Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01718197 · ClinicalTrials.gov registry record
Severe Asthma Research Program (SARP)- San Francisco Clinical Site
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 151
- Enrollment target
NCT01718197: Completed study, sponsored by University of California, San Francisco.
NCT01718197 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 151 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01718197 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 151 participants
- Enrollment target
Study Summary
The mission of SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.
Primary Outcome
Changes in lung function parameters over time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2012-11 |
| Est. Completion | 2021-03-01 |
What the finished NCT01718197 record still lists
NCT01718197 is an observational study that tracks outcomes without assigning an intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01718197 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01718197 about?
NCT01718197 is a clinical study titled "Severe Asthma Research Program (SARP)- San Francisco Clinical Site". The mission of SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.
What is the current status of trial NCT01718197?
This trial is currently completed. The enrollment target is 151 participants. The study started on 2012-11. Estimated completion is 2021-03-01.
Who is sponsoring clinical trial NCT01718197?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia